TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01222091

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match Propranolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Match Propranolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
Study: NCT03093207

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement will be performed to decontaminate root surface

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Open flap debridement will be performed to decontaminate root surface

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills over a period of 180 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: 3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100 mg of aspirin daily supplementation over a period of 180 days
Study: NCT04293510

Intervention type: PROCEDURE
Intervention: renal biopsy and blood sampling
Description: renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
Study: NCT01814878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/Acetaminophen ER
Description: 2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl/Acetaminophen IR
Description: 2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
Study: NCT01029990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone arm
Description: Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-test arm
Description: Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
Study: NCT04660825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A resistance band exercise programme
Description: A resistance band based exercise programme lasting six months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Maintained usual physical activity
Study: NCT01116024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATS 3f Enable Aortic Bioprosthesis Model 6000
Description: Replacement Aortic Heart Valve
Study: NCT02660671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email outreach
Description: Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email outreach
Description: Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email outreach
Description: Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
Study: NCT02872896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic, urologic or general surgery
Description: Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Orthopedic, urologic or general surgery
Description: Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
Study: NCT03341078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: Ibudilast capsules will be orally ingested twice daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsules will be orally ingested twice daily for 6 weeks.
Study: NCT02074345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-816
Description: TAK-816 intramuscular injection
Study: NCT04224636

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection, Bevacizumab Injection
Description: Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection, Bevacizumab Injection
Description: Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
Study: NCT01938924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GekoTM
Description: electrical neuromuscular stimulation
Study: NCT00519376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444H
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04445922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test-anastrozole tablet (Salutas Pharma GmbH)
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference-anastrozole tablet
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
Study: NCT01991028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled OligoG CF-5/20 DPI
Description: Inhalation with dry powder by Mia Monodose Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiolabelled OligoG CF-5/20 6% Solution
Description: Inhalation with aerosolised solution by nebuliser
Study: NCT01617174

Intervention type: BEHAVIORAL
Intervention: Webcore telephone survey system
Description: Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
Study: NCT01991067

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE virus vaccine
Description: TBE virus vaccine FSME Immun is used in both arms for the study population and the control group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE virus vaccine
Description: TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
Study: NCT01029574

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Platelet rich plasma
Description: Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
Study: NCT04062175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalosporin
Description: 72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalosporin
Description: 72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Tablets
Description: 72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
Study: NCT03555201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: protocol of soft tissues techniques

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular treatment control.
Description: Regular treatment control.
Study: NCT01920789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Description: Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
Study: NCT04252456

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan
Description: All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
Study: NCT01618994

Intervention type: PROCEDURE
Intervention: Performing robotic supracervical hysterectomy
Description: All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy

Intervention type: PROCEDURE
Intervention: Performing robotic supracervical hysterectomy
Description: All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy

Intervention type: PROCEDURE
Intervention: Performing robotic supracervical hysterectomy
Description: All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
Study: NCT02257944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Brief hospital-based intervention, rooted in motivational interviewing
Study: NCT06505070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational Games
Description: 40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played.
Study: NCT02960490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration
Study: NCT02257944

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: treatment as usual
Study: NCT03062683

Intervention type: OTHER
Intervention: Lactate, prolactin and creatine kinase conc.
Description: Lactate, prolactin and creatine kinase conc. in blood samples were measured

Intervention type: OTHER
Intervention: Lactate, prolactin and creatine kinase conc.
Description: Lactate, prolactin and creatine kinase conc. in blood samples were measured
Study: NCT00789139

Intervention type: DEVICE
Group type: OTHER
Intervention: ICM Implantation
Description: Sub cutaneous implantation of the ICM
Study: NCT02079181

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 d-FMAU
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fluorine F 18 d-FMAU PET/CT scan
Study: NCT02960490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous administration
Study: NCT03804814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Training
Description: Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers.
Study: NCT03296878

Intervention type: OTHER
Group type: OTHER
Intervention: Own-Price Elasticity
Description: The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.

Intervention type: OTHER
Group type: OTHER
Intervention: Cross-Price Elasticity
Description: The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
Study: NCT00191165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Doubled dosage with respect to the pre-enrollment (in-label) dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: In-label dosage
Study: NCT04257149

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hemorrhagic stroke group (group A)
Description: Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ischemic stroke group (group B)
Description: Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stroke mimic group (group C)
Description: Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
Study: NCT02538380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-B-FNA followed by EUS-FNA for LAG analysis
Study: NCT00641615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNF43-721
Description: Doses of 0.5mg, 1.0mg, 3.0mg/body/week
Study: NCT01586793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid2 Stimulator
Description: 1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid2 Stimulator
Description: 10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
Study: NCT03070587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Training for SAD
Description: The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
Study: NCT03507647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: MBCT is a manualised group skills-training program (Segal, Williams \& Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
Study: NCT00769873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days
Study: NCT02121873

Intervention type: DEVICE
Intervention: Nipple aspirator
Description: The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.

Intervention type: DEVICE
Intervention: Ductal lavage microcatheter
Description: Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.

Intervention type: DEVICE
Intervention: Blood draw
Description: Blood will be drawn and immediately processed for shipping to Covance for WGS.
Study: NCT03571386

Intervention type: BEHAVIORAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Description: Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed

Intervention type: BEHAVIORAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Description: Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed

Intervention type: BEHAVIORAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Description: Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
Study: NCT01911286

Intervention type: PROCEDURE
Intervention: Apnea test - Standard

Intervention type: PROCEDURE
Intervention: Apnea test - CPAP